In the majority of sporadic human melanomas, mutations activating the mitogen-activated protein kinase (MAPK/MEK) pathway (Figure 1) are present, affecting mainly BRAF, NRAS, or neurofibromin 1 (NF1) genes (see below). The gene discussed is NRAS; the disease is melanoma.